API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Alkeran-Generic (melphalan hydrochloride) is a DNA alkylating agent of the bischloroethylamine type. It is approved for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Lead Product(s): Melphalan Hydrochloride
Therapeutic Area: Oncology Product Name: Alkeran-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The event will feature, updated Focus trial data and the role of Hepzato™ Kit (melphalan hydrochloride for injection/Hepatic Delivery System) as a potential treatment for patients with hepatic-dominant metastatic ocular melanoma.
Lead Product(s): Melphalan Hydrochloride
Therapeutic Area: Oncology Product Name: Hepzato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2021
Details:
Delcath have reached the minimum endpoint target enrollment in the FOCUS trial and expects to announce top-line results around the middle of this year.
Lead Product(s): Melphalan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020